# Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

> **NCT00551421** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum
- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage III Colon Cancer
- Stage III Rectal Cancer
- Stage IV Colon Cancer
- Stage IV Rectal Cancer

## Interventions

- **BIOLOGICAL:** pertuzumab
- **BIOLOGICAL:** cetuximab
- **DRUG:** irinotecan hydrochloride
- **OTHER:** immunohistochemistry staining method
- **OTHER:** fluorescence in situ hybridization
- **OTHER:** gene expression analysis
- **OTHER:** mutation analysis
- **OTHER:** polymerase chain reaction
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00551421
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-11
- **Final completion:** 2012-06
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551421, "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00551421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*